


5-Aminolevulinic acid-d₂ hydrochloride

| | |
|---------------------------|--|
| Cat. No.: | HY-N0305S1 |
| CAS No.: | 187237-35-0 |
| Molecular Formula: | C ₅ H ₈ D ₂ ClNO ₃ |
| Molecular Weight: | 169.6 |
| Target: | Apoptosis; Autophagy; Mitophagy; Endogenous Metabolite; Isotope-Labeled Compounds |
| Pathway: | Apoptosis; Autophagy; Metabolic Enzyme/Protease; Others |
| Storage: | -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | 5-Aminolevulinic acid-d ₂ (hydrochloride) is deuterium labeled 5-Aminolevulinic acid (hydrochloride). |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Eyupoglu, I.Y., et al., Improving the extent of malignant glioma resection by dual intraoperative visualization approach. *PLoS One*, 2012. 7(9): p. e44885.
- [3]. Stummer, W., et al., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol*, 2006. 7(5): p. 392-401.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA